Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Christopher T RitchlinLaura C CoatesIain B McInnesPhillip J MeaseJoseph F MerolaYoshiya TanakaAkihiko AsahinaLaure GossecAlice B GottliebRichard B WarrenBarbara InkRajan BajracharyaVishvesh ShendeJason CoarseRobert B M LandewePublished in: Annals of the rheumatic diseases (2023)
NCT03895203.